| INTRODUCTION
Epidemiologic data strongly support an association between statin use and reduced risk of advanced prostate cancer. 1, 2 In addition, studies have shown that statin use in men diagnosed with prostate cancer is associated with a lower risk of prostate cancer recurrence 3 and decreased prostate cancer-specific mortality. 4 However, the vast majority of past research was conducted in white men, and studies exploring these associations in minority-enriched populations are few.
Moreover, few prior studies of statin use and prostate cancer incorporated data for high serum cholesterol, a primary indication for use of the cholesterol-lowering statins.
Previously, we reported that statin use was inversely associated with prostate cancer aggressiveness in the population-based, minority-enriched North Carolina-Louisiana Prostate Cancer Project (PCaP). 5 Herein, using data from the PCaP follow-up study, the Health Care Access and Prostate Cancer Treatment in North Carolina (HCaP-NC) cohort, we investigated the association between statin use at diagnosis and risk of prostate cancer progression, overall and by race.
In secondary analysis, we examined associations between high serum cholesterol and risk of prostate cancer progression, overall and stratified by statin use. We hypothesized that (1) statin use would be associated with reduced risk of prostate cancer progression and (2) high serum cholesterol would be associated with increased risk of prostate cancer progression, particularly among non-statin-users.
| MATERIALS AND METHODS

| Study population
The North Carolina-Louisiana Prostate Cancer Project (PCaP) is a population-based cohort of European American (EA) and African 6 Research subjects gathered all prescription medications used in the 2-week period prior to interview and presented them to the research nurse at the time of interview for documentation of statin use. Statin dose was converted to a simvastatin dose-equivalent, as previously described, 8 and dichotomized as low/normal (≤20 mg simvastatin dose-equivalent) versus high dose (>20 mg simvastatin dose-equivalent). 5 Data regarding duration of statin use were not collected in this study.
Questionnaires administered in follow-up year 1 asked research subjects "Has a doctor or health professional EVER told you that you have or had high cholesterol?" In follow-up years 2 and 3, research subjects were asked this same question. If their response was "yes,"
they had the option to indicate "I already had this at my last interview, but since then it has: (A) gotten better; (B) gotten worse; or (C) stayed the same." We recoded high cholesterol as ever versus never. Among those ever told that they had high cholesterol, we further categorized this variable as those with cholesterol levels that improved during the follow-up period versus those whose cholesterol levels stayed the same. We did not make a separate category for men with worsening cholesterol levels as numbers were few (n = 12) and instead excluded them from the relevant analyses. Research subjects treated initially with radiation (external beam or brachytherapy, n = 244; 28%) were categorized as having a prostate cancer progression event if they had BCR or received secondary treatment. BCR was determined using the Phoenix definition and was defined as nadir (lowest PSA achieved after radiation) + 2 ng/mL. 11 Men with BCR were recorded as having prostate cancer progression at the first PSA that was 2 ng/mL above nadir. Secondary treatment for prostate cancer included ADT or chemotherapy. Adjuvant ADT, defined as ADT initiated ≤1 year after start of radiation, was not considered secondary treatment. Research subjects were recorded as having a prostate cancer progression event on the date the secondary treatment began.
Prostate cancer progression was not determined for men if they: (i) received no treatment or only watchful waiting (n = 59); (ii) received ADT as the primary treatment (n = 31); (iii) underwent radical prostatectomy but no PSAs were measured within 6 months of surgery (n = 33); or (iv) information essential to determine progression status was missing, including missing treatment date, or PSA values (n = 24). Ultimately, prostate cancer progression was determined for 672 (82%) research subjects in HCaP-NC.
| Statistical analysis
Of 672 men with progression data, we excluded three men who were missing BMI data, leaving 669 research subjects included in our analysis. We examined differences in baseline characteristics according to statin use and high cholesterol status using chi-square tests for categorical variables, student's t-tests for continuous, normally distributed variables and rank sum tests for continuous non-normally distributed variables.
We conducted Cox proportional hazards analysis to test the association between statin use and dose at diagnosis and risk of prostate cancer progression, overall and stratified by race. For multivariable models, covariates were selected based on known confounders in the literature. We performed backwards selection (using P < 0.1 as the criteria to retain covariates) to build our final model, which included age at diagnosis (continuous), race (EA, AA; except for analyses stratified by race) and obesity status (BMI <30,
. We examined log-log plots and assessed Schoenfeld residuals to confirm that none of our exposure variables or covariates violated the proportional hazards assumption. Given data supporting radio-sensitizing properties of statins, 12 we conducted exploratory analysis stratified by primary treatment type (RP vs radiation), but this produced similar findings (data not shown). We explored sensitivity analyses where models were further adjusted for tumor aggressiveness (low/intermediate, high) and prostate cancer treatment (RP, radiation). In addition, we further adjusted statin models for selfreported history of high cholesterol. As this did not substantially alter our results, these findings are not presented. We also examined whether changes in cholesterol levels during the follow-up period modified the association between statin use at diagnosis and risk of prostate cancer progression.
In secondary analysis, using the same approach as described for statins, we examined the association between high cholesterol and risk of prostate cancer progression, overall and stratified by statin use at diagnosis. We explored health literacy and perceived access to care as effect modifiers of the association between self-reported high cholesterol and prostate cancer progression. We tested for interaction between these variables and high cholesterol for predicting risk of progression by incorporating a cross-product term into the model and testing its significance using the Wald test. Given that these were secondary analyses, results were not adjusted for multiple testing.
Statistical analyses were conducted using STATA version 13.1 (Stata Corp., College Station, TX). Statistical significance was two-sided with P < 0.05. or tumor aggressiveness) differed by statin use (all P ≥ 0.17). However, statin users were more likely to report a history of prostate cancer screening than non-users (P = 0.017). Relative to non-users, statin users were more likely to receive radiation as primary treatment for prostate cancer (P < 0.001). There were no differences in first-degree family history of prostate cancer, education, income level, or smoking status by statin use. However, relative to non-users, statin users were more likely to be obese (P < 0.001) and more likely to have at least one comorbid condition (P < 0.001), including diabetes (27% vs 14%; P < 0.001) and high cholesterol (91% vs 48%; P < 0.001; Table 1 ).
Relative to statin users who reported high cholesterol, statin users who did not report a history of high cholesterol (n = 22; 9%) were more likely to have diabetes (41% vs 25%), a coronary heart disease risk equivalent. 13 Research subjects reporting a history of high cholesterol comprised 64% of our cohort (Supplementary Table S1 ). Age, race and tumor characteristics did not differ by self-reported history of high cholesterol, and neither did primary treatment type, education, income, health literacy, or perceived access to care. However, men with high cholesterol were more likely to be obese (42% vs 31%) and have at least one co-morbid condition, including diabetes (23% vs 11%). Just over half (52%) of men reporting a history of high cholesterol were statin users at diagnosis (Supplementary Table S1 ).
| Statin use and risk of prostate cancer progression
Of 669 research subjects, 138 (21%) experienced prostate cancer progression. Median follow-up among men who did not progress was 3.8 years. Kaplan Meier curves showed no association between statin use at diagnosis and risk of prostate cancer progression (log-rank P = 0.892; Figure 1A ). Table S2 ).
| High cholesterol and risk of prostate cancer progression
Our secondary analysis showed that high cholesterol was not associated with risk of prostate cancer progression on univariable analysis (log-rank P = 0.245; Figure 1B ). High cholesterol remained unassociated with risk of progression after adjusting for age, race, and obesity status (HR 0.80; 95%CI 0.57-1.14; Table 3 Table S3 ). Furthermore, analyses stratified by perceived access to care revealed that self-reported high cholesterol was inversely associated with risk of prostate cancer However, the majority of prior studies were conducted in white men, and thus this association has not been well tested in AAs. Herein, using data from the HCaP-NC population-based study comprising 42%
AAs, we found that statin use at the time of diagnosis was unrelated to risk of prostate cancer progression. As such, our results do not support an association between statin use and risk of prostate cancer progression in this minority-enriched population.
Only two prior studies, to our knowledge, examined associations between statin use and prostate cancer risk or progression in AAs. The prospective Southern Community Cohort Study, comprised of 67% AAs, reported no significant association between statin use and risk of either overall or advanced prostate cancer, with no differences by race. 14 An analysis of the Veterans Administration-based SEARCH database, comprised of 44% AAs, reported a significant inverse association between post-diagnosis statin use and risk of biochemical recurrence in non-AA, but not in AA men. 3 In the present study, racestratified analyses did not support an association between statin use and risk of progression overall, or in EAs or AAs. If future studies find that associations between statin use and prostate cancer-specific outcomes are weaker in AAs, this may help to explain the lack of association between statin use and prostate cancer progression in the present analysis which contained large numbers of AAs. Possible racial differences in associations between statin use and prostate cancerspecific outcomes, if confirmed by future studies, could be attributable
to as yet undefined biologic (eg, racial differences in molecular tumor subtype 15 ) and/or non-biologic (eg, racial differences in adherence to statin therapy, health-seeking behaviors) mechanisms. 16 However, the findings from the present study are far from definitive and future studies with larger sample sizes and longer follow-up will be required to test the association between statins and prostate cancer by race. Adjusted for age, race, and obesity status (except for analyses stratified by race which are adjusted for age and obesity only). b Low/normal dose ≤20 mg simvastatin or equivalent; high dose >20 mg simvastatin or equivalent.
In contrast to the strong epidemiologic evidence linking statins and prostate cancer, data from human studies supporting a role for serum cholesterol in prostate cancer are less clear. Results from a large consortium showed a weak association between high serum cholesterol and increased risk of high-grade prostate cancer, 17 and several large studies examining the effect of high serum cholesterol on prostate cancer-specific mortality reported null to weakly positive findings. [18] [19] [20] However, a recent analysis of data from a series of RP patients in Switzerland found that high levels of low-density lipoprotein (LDL), measured the day before surgery, were associated with a reduced risk of BCR. 21 Another RP series from Japan also found that high serum cholesterol levels, measured shortly after diagnosis, were associated with reduced risk of BCR. 22 These authors acknowledged that their findings could be explained by reverse causation, where cholesterol uptake by the growing tumor can lower serum levels thereby producing a spurious inverse association between high cholesterol and more aggressive disease. 23 Our findings from the present study also showed an inverse direction of association between a self-reported history of high cholesterol and risk of prostate cancer progression. However, we do not expect that self-reported history of high cholesterol would be affected by tumor aggressiveness, and therefore our findings cannot be explained by reverse causality.
Instead, we found that the inverse association between high cholesterol and risk of progression was more pronounced in statin users as well as in men with higher health literacy levels and greater perceived access to care. Only 55% of the 78 million US adults with high cholesterol are taking medication to control cholesterol levels, 24 as reflected in the present study where 52% of men with high cholesterol were taking statins. Therefore, it may be that men who selfreported a history of high cholesterol but who were taking statins to control cholesterol levels were more engaged in their healthcare, and that this and other related behaviors contributed to improved prostate cancer-specific outcomes in these men.
Our findings should be considered in the context of study limitations. Statin use was assessed roughly 3 months after prostate cancer diagnosis, and we do not have data on duration of statin use before diagnosis nor were we able to assess whether statin users continued on statins during follow-up. Any misclassification of statin use would be expected to be non-differential with regard to the progression outcome and would likely bias associations toward the null. Second, with a median follow-up of 3.8 years, we were unable to examine the effect of statin use on risk of longer-term outcomes including prostate cancer-specific mortality. Third, our sample size was somewhat limited and we may have had insufficient power to detect significant associations, particularly for stratified analyses. Fourth, our findings related to serum cholesterol and risk of progression should be interpreted with caution given that these were secondary analyses, not adjusted for multiple testing. Finally, while our study consisted mainly of lower risk prostate cancer patients, the population-based study design maximized its representativeness with respect to prostate cancers diagnosed in North Carolina during this period. These limitations are balanced by a number of important strengths, which include the racial and socioeconomic diversity of HCaP-NC. We were able to incorporate data regarding health literacy and perceived access to care as potential effect modifiers of associations between selfreported high cholesterol and prostate cancer progression, whereas many observational studies do not have access to these data.
Moreover, previous studies have mostly been limited to a single treatment modality (e.g. RP 3 ), whereas this study includes men treated with RP or radiation and thus may be more generalizable to all prostate cancer patients.
| CONCLUSIONS
Our study does not support an inverse association between statin use and risk of prostate cancer progression in this minority-enriched cohort. Future studies, potentially incorporating biomarkers to classify prostate cancer subtypes with distinct biology, are required to identify specific populations that could benefit from statin use with respect to prostate cancer-specific outcomes.
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